PRODUCT INFORMATION



Rofecoxib-d₅

Item No. 2890Ŏ

CAS Registry No.:	544684-93-7	
Formal Name:	4-[4-(methylsulfonyl)phenyl]-3-(phenyl-d ₅)-	
	2(5H)-furanone	ĭ />─-Ś=o
MF:	C ₁₇ H ₉ D ₅ O ₄ S	
FW:	319.4	
Chemical Purity:	≥98% (Rofecoxib)	
Deuterium		
Incorporation:	≥99% deuterated forms (d ₁ -d ₅); ≤1% d ₀	
Supplied as:	A solid	
Storage:	-20°C	Ď
Stability:	≥4 years	

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Rofecoxib-d₅ is intended for use as an internal standard for the quantification of rofecoxib (Item No. 10010260) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Rofecoxib-d₅ is supplied as a solid. A stock solution may be made by dissolving the rofecoxib-d₅ in the solvent of choice, which should be purged with an inert gas. Rofecoxib- d_5 is soluble in organic solvents such as DMSO and acetonitrile.

Description

Rofecoxib is a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2 over COX-1 with IC_{50} values of 0.018 and >15 μ M, respectively, for production of prostaglandin E_2 (PGE₂; Item No. 14010) in CHO cells expressing the recombinant human enzymes.¹ In vivo, rofecoxib inhibits carrageenan-induced paw edema and hyperalgesia (ID₅₀s = 1.5 and 1.0 mg/kg, respectively), LPS-induced pyresis (ID₅₀ = 0.24 mg/kg), and *M. butyricum*-induced arthritis (ID₅₀ = 0.74 mg/kg per day) in rats. Formulations containing rofecoxib were previously used in the treatment of pain and arthritis.

Reference

1. Chan, C.C., Boyce, S., Brideau, C., et al. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J. Pharmacol. Exp. Ther. 290(2), 551-560 (1999).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 12/08/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM